Search

This experiment evaluated the dose and payout pattern of trenbolone acetate (TBA) and estradiol-17β (E2) on LM mRNA expression of adenosine monophosphate-activated protein kinase-ɑ (AMPK-ɑ), C/EBPβ, G protein-coupled receptor 41(GPR41), G protein-coupled receptor 43 (GPR43), PPARγ, and stearoyl CoA desaturase (SCD) in finishing feedlot steers as indicators of adipogenesis and marbling development. British · Continental steers (n = 168; 14 pens/treatment; initial BW = 362 kg) were used in a randomized complete block design. Treatments included: no implant (NI), Revalor-S (REV-S; 120 mg TBA + 24 mg E2), or Revalor-XS (REV-X; delayed release implant: 80 mg TBA + 16 mg E2 [uncoated], 120 mg TBA + 24 mg E2 [coated], 200 mg TBA + 40 mg E2 [total]). Steers were fed 1 time daily for an average of 164 d. The LM biopsies were collected (1 steer/pen) on d -1, 27, 55, and 111 relative to timing of implant. Total RNA was isolated from each sample and real-time quantitative PCR was used to measure quantity of AMPK-ɑ, C/EBPβ, GPR41, ,it, PPARγ, and SCD mRNA. No implant · day interactions were detected (P ≥ 0.19) in this experiment. Day impacted the mRNA expression of all adipogenic genes (P ≤ 0.02). The main effect of implant tended (P = 0.09) to influence expression of AMPK-ɑ, REV-X had an 8.8% increase over NI and an 18.7% increase over REV-S. Implant influenced (P = 0.03) mRNA expression of GPR41, expression of GPR41 for the REV-X treatment was not different (P > 0.10) from NI, and both were greater (P ≤ 0.05) than REV-S (1.13, 1.00, and 0.67 ± 0.224 arbitrary units) for REV-X, NI, and REV-S, respectively. Implant also influenced (P = 0.02) expression of GPR43, expression of GPR43 for REV-X was not different (P > 0.10) from NI, and both were greater (P ≤ 0.05) than REV-S (1.27, 1.07, and 0.72 ± 0.234 arbitrary units) for REV-X, NI, and REV-S, respectively. Implant influenced (P = 0.02) mRNA expression of PPARγ in LM tissue, expression of PPARγ for REV-X was not different (P > 0.10) from NI, and both were greater (P ≤ 0.05) than REV-S (1.09, 1.02, and 0.69 ± 0.195 arbitrary units) for REV-X, NI, and REV-S, respectively. The REV-X steers received the greatest anabolic dose of TBA + E2 without detriment to marbling scores. The increased mRNA expression of adipogenic genes for REV-X steers suggest that the delayed and gradual release of anabolic stimulants associated with REV-X might have mitigated decreases in marbling generally attributed to multiple combined TBA + E2 implants. [ABSTRACT FROM AUTHOR]

Our objectives were to evaluate the dose/payout pattern of trenbolone acetate (TBA) and estradiol-1713 (E2) implants and feeding of zilpaterol hydrochloride (ZH) on performance and carcass characteristics of finishing beef steers. A randomized complete block design was used with a 3 × 2 factorial arrangement of treatments. British × Continental steers (n = 168; initial BW = 362 kg) were blocked by BW and allotted randomly to 42 pens (7 pens/treatment; 6 pens/ block; 4 steers/pen). The main effects of treatment were implant [no implant (NI); Revalor-S (REV-S; 120 mg of TBA + 24 mg of E2); and Revalor-XS (REV-X; 200 mg of TBA + 40 mg of E2)I and ZH (0 or 8.3 mg/ kg of DM for 20 d with a 3-d withdrawal before slaughter). Blocks were split into 2 groups, and block groups were fed for either 153 or 174 d. No implant × ZH interactions were noted for cumulative performance data. Overall, shrunk final BW (567, 606, and 624 kg for NI, REV-S, and REV-X, respectively), ADG (1.25, 1.51, and 1.60 kg), and G:F (0.14, 0.16, and 0.17) increased (P < 0.05) as TBA and E2 dose increased. Implanting increased (P < 0.05) DM1, but DM1 did' not differ (P > 0.10) between REV-S and REV-X (8.8 for NI vs. 9.4 kg/d for the 2 implants). From d ito 112 of the feeding period, implanting increased (P < 0.05) ADG and G:F, but REV-S and REV-X did not differ (P> 0.10). From d 112 to end, ADG increased by 19% (P < 0.05) and G:F was 18% greater (P < 0.05) for REV-X vs. REVS. Carcass-adjusted final BW (29-kg difference), ADG (0.2-kg/d difference), and G:F (0.02 difference) were increased (P < 0.05) by ZH, but daily DM1 was not affected by feeding ZH. Hot carcass weight was increased (P < 0.05) by ZH (19-kg difference) and implant, with REV-X resulting in the greatest response (HCW of 376 for NI vs. 404 and 419 kg for REV-S and REV-X, respectively; P < 0.05). An implant x ZH interaction (P = 0.05) occurred for dressing percent (DP). Without ZH, implanting increased DP, but DP did not differ (P > 0.10) between REV-X and REV-S. With ZH, REV-X increased (1.7%; P < 0.05) DP vs. NI and REV-S. Marbling score, 12th-rib fat, and KPH were not affected (P > 0.10) by implant or ZH. Overall, treatment increased steer performance and HCW in an additive fashion, suggesting different mechanisms of action for ZH and steroidal implants. In addition, a greater dose of TBA + E2 and extended payout improved steer performance and HCW. [ABSTRACT FROM AUTHOR]

We previously showed that a combined trenbolone acetate (TBA)/estradiol-17β (E2) implant significantly increases IGF-I mRNA levels in the LM of feedlot steers by 28 d after implantation. Here we compare the effects of E2 (25.7 mg), TBA (120 mg), and combined TBA (120 mg)/E2 (24 mg) implants on IGF-I, ICF-I receptor (IGFR-1), estrogen receptor (ER)-α and androgen receptor (AR) mRNA levels in the LM of steers. Twenty yearling crossbred steers with an average initial BW of 421.1 ± 3.6 kg were stratified by BW and randomly assigned to 1 of 4 treatments: 1) nonimplanted, control; 2) implanted with TBA and E2; 3) implanted with E2; or 4) implanted with TBA. Steers were weighed weekly starting on d 0, and muscle biopsy samples were taken from each steer on d 0 (before implantation), 7, 14, and 28. Ribonucleic acid was prepared from each sample and real-time reverse transcription-PCR was used to determine the levels of IGF-I, IGFR-1, ER-α, and AR mRNA. Body weight of implanted steers, adjusted by using d-0 BW as a covariant, tended (P = 0.09) to be greater than that of control steers. On d 7 and 28, IGF-I mRNA levels were greater (58 and 78%, respectively; P < 0.009) in E2-implanted animals than in control steers. Similarly, on d 28 the LM IGF-I mRNA level was 65% greater (P = 0.017) in TBA/E2-implanted steers than in control animals. In contrast, the TBA implant did not increase (P = 0.99) LM IGF-I mRNA levels after 28 d of implantation. Muscle IGFR-1, AR, and ER-α mRNA levels were not different (P > 0.47) in any of the treated groups compared with the control group. These data suggest that E2 is responsible for the increased muscle ICF-I mRNA level observed in steers implanted with a combined TBA/E2 implant. [ABSTRACT FROM AUTHOR]